Axogen Quarterly Cash Flow Statement
NASDAQ: AXGNHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 36.38 +0.69%
Axogen free cash flow
In the quarter ended Jun 30, 2026, Axogen generated $7.2 million of operating cash flow and spent $893,000 on capital expenditures. That left free cash flow of $6.3 million, a free-cash-flow margin of 9.1% of revenue. Free cash flow was down 9.7% from the prior year's $7.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Axogen cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -1.52M | -19.58M | -13.16M | 708.00K | 579.00K | -3.83M | 450.00K | -1.86M | -1.92M | -6.63M | -3.89M | -4.09M |
| Net Income growth (YoY) | -361.83% | — | -3023.56% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.61M | 1.60M | 1.63M | 1.64M | 1.66M | 1.73M | 1.64M | 1.65M | 1.66M | 1.52M | 1.56M | 1.15M |
| Stock-Based Compensation | 8.77M | 6.84M | 16.61M | 5.42M | 5.17M | 2.91M | 3.08M | 5.00M | 3.91M | 3.92M | 1.33M | 4.75M |
| Change in Working Capital | -1.00M | -3.90M | -4.53M | -4.33M | 389.00K | -14.20M | 3.43M | -864.00K | 483.00K | -11.49M | 1.33M | 1.40M |
| Operating Cash Flow | 7.22M | 1.56M | 3.04M | 3.22M | 7.73M | -13.18M | 8.73M | 3.90M | 4.17M | -12.27M | -211.00K | 1.63M |
| Capital Expenditures | -893.00K | -2.79M | -1.25M | -1.52M | -722.00K | -256.00K | -670.00K | -597.00K | -910.00K | -924.00K | -1.46M | -3.69M |
| Investing Cash Flow | 500.00K | -15.96M | 4.04M | -3.75M | -6.95M | 1.34M | -813.00K | -5.00M | -1.23M | -3.25M | -277.00K | 5.99M |
| Debt Repaid | 0 | -48.59M | — | — | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 4.20M | 59.51M | 4.57M | 2.39M | 1.16M | 2.38M | 970.00K | 572.00K | 544.00K | 204.00K | 418.00K | 5.00K |
| Net Change in Cash | 11.92M | 45.11M | 11.65M | 1.87M | 1.94M | -9.46M | 8.89M | -527.00K | 3.48M | -15.31M | -70.00K | 7.63M |
| Free Cash Flow | 6.33M | -1.22M | 1.79M | 1.70M | 7.01M | -13.44M | 8.06M | 3.30M | 3.25M | -13.19M | -1.67M | -2.06M |
This table shows 12 quarterly periods of Axogen's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AXGN's reporting calendar. What is a cash flow statement?